Appendix 5 Vaccine selection for the European banks David Paton, WRL Pirbright Issues
• • • • • • • • • •
Do we have adequate global information on outbreaks and their characteristics? Do we maximise information from available surveillance? Are the matching tests we do sufficient and reliable? How can we utilise data from other laboratories - collaboration versus competition? How do we prioritise risks from particular strains? How many doses of vaccines do we need? What useful collaboration can be undertaken between vaccine banks? Is there a prospect of more sharing of antigen reserves? Do we know enough about what vaccines are used in endemic countries and about their effectiveness? Tensions/conflicts between commercial vaccine producers and reference laboratories and vaccine banks.
Actions underway
•
EU coordination action starting January 2005 o Foster collaboration between reference labs o Establish systems for sharing information o Foster collaboration between vaccine bank managers o Develop model systems for evaluating risks of importing FMD
•
EU Improcon and related research projects o Develop improved vaccine matching techniques o Measure cross-protection directly and evaluate correlation with in vitro matching techniques
•
OIE ad hoc vaccine group o See below
The Mission statement for the OIE ad hoc vaccine group was adopted as: "To facilitate information exchange and harmonisation of methods and standards to assist countries in the establishment of vaccine banks, with special emphasis on FMD; including the development of a network of banks for exchange of information on cross-protection of vaccine antigens and to resolve issues relating to potential supply of antigens and vaccines between banks and regions”. The following Terms of reference were agreed upon: 1.
To develop guidelines for International Standards for vaccine banks for proposal as a Chapter of the Terrestrial Manual.
2.
To develop guidelines for International standards, specific to FMD antigen and vaccine banks, to be proposed as an additional component within the FMD Chapter 2.1.1 in the Terrestrial Manual.
3. To develop guidelines on harmonisation of virus strain characterisation, to provide other information relating to cross-protection against infection with circulating FMD viruses and to assist in the identification and selection of antigens for inclusion in FMD vaccines and antigen banks. 4. To provide advice on future development and operation of a potential vaccine bank network. 5. To provide advice to the OIE on issues relating to networking of the OIE and FAO regional and international FMD Reference Laboratories.
55
